Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

Gaucher Disease Clinical Trial

Official title:

A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00258778
• Other study ID #: P-01-2005
• Status: Completed
• Phase: Phase 1
• First received: November 23, 2005
• Last updated: December 4, 2006
• Start date: November 2005
• Est. completion date: January 2006

Study information

• Verified date: December 2006
• Source: Protalix
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD)leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer)in the cells of the monocyte-macrophage system.

This is the first trial to utilize a recombinant active form of lysosomal enzyme, glucocerebrosidase, (human prGCD)which is expressed and purified in a bioreactor system from transformed carrot plant root cell line.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: January 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy male or female between 18 and 45 years of age.

2. Female subjects must agree to use a medically acceptable method of contraception at all times during the study and must have a negative serum pregnancy test at baseline and during the study period.

3. Females of child-bearing potential must be non-pregnant and not lactating and using adequate birth control such as oral contraceptives.

4. Negative laboratory tests for HIV, HBsAg or HCV.

5. Naive to any previous recombinant protein therapy.

6. Provide written informed consent.

7. Have the ability to understand the requirements of the study and to comply with the study protocol and dosing regimen.

Exclusion Criteria:

1. Have clinical evidence of any active significant disease that could potentially compromise the ability of the investigator to evaluate or interpret the effects of the study treatment on safety assessment and thus increase the risk to the subject to unacceptable levels.

2. Are pregnant or nursing.

3. Presence of any acute or chronic diseases.

4. Have a history of any allergies.

5. Have been exposed to long-term steroid treatment.

6. Had a minor operation in the last 6 months.

7. Have ever been exposed to any previous recombinant protein therapy.

8. Have received immuno-suppressive treatment.

9. Have a positive HIV, HBsAG and HCV laboratory result.

10. Use any medication other than vitamins or oral contraceptives (for female).

11. Have participated in another clinical trial during the previous 3 months

12. Have history of alcohol or drug abuse.

13. Are considered by the Investigator to be unsuitable candidate for this study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gaucher Disease

Intervention

Drug:
• Human Glucocerebrosidase (prGCD)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Protalix

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety as measured by:
Primary	adverse events
Primary	change in vital signs
Primary	physical examination
Primary	laboratory test results
Secondary	Pharmacokinetic parameters
Secondary	Immunological profile including: IgE, anti human prGCD antibodies, eosinophils and proteinuria